Evolving Role of Double and Triple Therapy With GLP 1 Receptor Agonists in Obesity and Cardiovascular Disease ScienceDirect Unlocking the Power of Cagrilintide: A Deep Dive Into Dosage Schedules and What to Expect Feast In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Full article: Pharmacotherapy for Obesity: Recent Updates MAA Semaglutide and Cagrilintide vs Tirzepatide.docx